Regardless of the nature of full resistance mechanisms, early non-genetic ibrutinib adaptation through Akt phosphorylation and MAPK pathway activation is likely to play a key role in maintaining a viable CLL cell reservoir. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.